Discover The Possibilities in
Non-Hodgkin Lymphoma and
Chronic Lymphocytic Leukemia

Call to Learn More +1 844 627 7246

Incyte is a leader in the discovery and development of therapies for patients with cancer. Currently Incyte is investigating a potential treatment option to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant. DLBCL is the most common type of non-Hodgkin lymphoma (NHL).

About the Program
About the program

The MIND program consists of multiple clinical trials that are evaluating tafasitamab and another drug called parsaclisib as part of different treatment strategies for patients with NHL or chronic lymphocytic leukemia (CLL). Two trials were recently initiated to evaluate the safety and efficacy of these 2 drugs for people with NHL or CLL who have already tried other treatment options.

About the Disease
What is the disease?

Non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are types of cancer that start in the body’s white blood cells, which are also known as “lymphocytes.”

What are the symptoms?

NHL and CLL share many symptoms, including swollen lymph nodes, abdominal pain, fatigue, fever, night sweats, and weight loss.6,7

What causes the disease?

NHL usually starts in white blood cells located in the lymphatic system, which is part of the body’s immune system. CLL typically starts in white blood cells located in the bone marrow and then moves into the bloodstream.

Copyright 2022 Incyte

Powered by: